Please contact us for more information or to learn if you are eligible to participate.
The purpose of the MASTER-2 study is to evaluate the effectiveness, safety and Patient-Reported Outcomes (PROs) of cladribine tablets in participants with relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS), who transition to cladribine tablets after suboptimal response to any oral or infusion Disease-Modifying Drugs (DMDs) approved in the United States (US) for RMS in a real-world-setting.
Principal Investigator | Roberto A. Cruz Saldana, M.D. |
Co-PI | Esmeralda Cordoso-Mendoza |
Sponsor | EMD Serono |
Type of Trial | Observational |